Akin Advises Pharmakon Advisors in $200 Million Term Loan Facility for Kestra Medical Technologies

July 15, 2026

Reading Time : 1 min

Contact:

Alexandra Field

Director of Communications

Roseanne Green

Senior Communications Manager

(New York) – Akin advised Pharmakon Advisors, LP, a leading investor in non-dilutive debt for the life sciences industry, and the BioPharma Credit funds in connection with an up to $200 million five-year term loan facility to Kestra Medical Technologies, Ltd., a leading wearable medical device and digital healthcare company, with the first tranche of $75 million funded at closing.

The Akin team was led by tax partner Geoffrey Secol and included fellow tax partners Stuart Leblang, David Snyder and Ryan Katz, senior counsel Miriam Foley and associates Joshua Elkouby and John Kwack; international trade partner Nnedinma Ifudu Nweke; health care & life sciences partner Nate Brown, senior counsel Jo‑Ellyn Klein and associate Jenna Becker; and corporate associates Casey Braden and Yossi Abadi.

 For additional information on the transaction, please click here.    

Akin is a leading international law firm with more than 1,100 lawyers in offices throughout the United States, Europe, and the Middle East.  

###

Share This Insight

Related Services, Sectors, and Regions

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.